Physician profile
Robert L Marsh
NPI 1730157371
$4,741.19
in general payments reported to CMS, 2019-2025
45 companies · $662 in 2025
The $662 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $18.92 · 2020: $176 · 2021: $28.22 · 2022: $23.75 · 2023: $699 · 2024: $3,133 · 2025: $662.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,170 · Consulting Fee: $1,238 · Education: $87.34.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,169.90 |
| Consulting Fee | $1,237.50 |
| Education | $87.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beigene USA, INC. | $1,309.88 | 2023-2024 | Brukinsa |
| Novartis Pharmaceuticals Corporation | $541.96 | 2020-2025 | |
| Janssen Biotech, INC. | $405.96 | 2020-2025 | Darzalex, Talvey, Tecvayli |
| Pfizer INC. | $199.07 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $178.04 | 2020-2025 | Tagrisso, Enhertu |
| Merck Sharp & Dohme LLC | $146.65 | 2023-2024 | Keytruda, Lynparza |
| Takeda Pharmaceuticals U.S.A., INC. | $120.80 | 2023-2024 | Alunbrig, Iclusig, Fruzaqla |
| Daiichi Sankyo INC. | $117.98 | 2024-2025 | Enhertu |
| Eisai INC. | $113.18 | 2024-2025 | |
| Genentech USA, INC. | $110.52 | 2020-2024 | Lunsumio, Columvi, Polivy |
| Incyte Corporation | $98.15 | 2023-2024 | Jakafi, Monjuvi |
| Tempus Ai, INC | $87.06 | 2024 | Xt Cdx |
| Bard Peripheral Vascular, INC. | $84.78 | 2024-2025 | Trek |
| Astellas Pharma US INC | $81.04 | 2023-2024 | Padcev, Cresemba |
| Celgene Corporation | $80.46 | 2023-2025 | Reblozyl, Opdivo, Pomalyst |
Show all 44 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Marsh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.